Actovegin Shows Promise for Cognitive Recovery After Stroke in Major Clinical Trial
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
Summary
This major clinical trial investigated whether Actovegin, a blood-derived therapeutic, could help restore cognitive function in stroke survivors experiencing persistent thinking and memory problems. The study enrolled 503 participants who had suffered recent strokes and were experiencing post-stroke cognitive impairment. Participants received either Actovegin or placebo treatment for six months, starting with IV infusions in the hospital followed by oral tablets at home. Researchers then monitored patients for an additional six months to see if cognitive improvements lasted after treatment ended. The trial specifically examined whether Actovegin could provide symptomatic relief for cognitive issues and potentially prevent progression to dementia in this vulnerable population.
Detailed Summary
This completed clinical trial examined whether Actovegin could improve cognitive function in stroke survivors experiencing persistent thinking and memory problems. Post-stroke cognitive impairment affects many stroke survivors and can significantly impact quality of life and independence.
The randomized, placebo-controlled study enrolled 503 participants who had suffered recent ischemic strokes and were experiencing cognitive difficulties. The trial design included a six-month active treatment period followed by a six-month observation period to assess lasting effects.
Participants received either Actovegin or placebo, beginning with intravenous infusions while hospitalized, then transitioning to oral tablets after discharge. This dual-phase approach ensured consistent dosing during both acute recovery and longer-term rehabilitation phases.
The study measured cognitive improvements and explored whether Actovegin could prevent progression to dementia in this high-risk population. Researchers also evaluated effects on other stroke-related outcomes and carefully monitored safety throughout the treatment period.
For longevity and brain health optimization, this research addresses a critical gap in post-stroke care. Cognitive impairment after stroke can accelerate aging processes and reduce healthspan significantly. The trial's focus on both immediate cognitive benefits and long-term dementia prevention aligns with key longevity goals of maintaining cognitive function throughout aging. While results aren't detailed here, this research represents important progress in developing interventions that could help stroke survivors maintain mental sharpness and independence, potentially extending both lifespan and healthspan for this vulnerable population.
Key Findings
- 503 stroke survivors completed six-month Actovegin treatment with additional six-month follow-up
- Study used dual-phase dosing: IV infusions during hospitalization, then oral tablets at home
- Trial explored both immediate cognitive benefits and long-term dementia prevention potential
- Research focused on post-stroke cognitive impairment affecting quality of life and independence
Methodology
This was a randomized, placebo-controlled trial enrolling 503 participants over approximately 2.5 years. The study featured a six-month active treatment period followed by six months of observation to assess sustained effects.
Study Limitations
Results and statistical significance are not provided in this summary, limiting assessment of clinical efficacy. The study focused specifically on ischemic stroke patients, so findings may not apply to hemorrhagic stroke survivors or other cognitive impairment causes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.